The Current Status of Mesenchymal Stromal Cells: Controversies, Unresolved Issues and Some Promising Solutions to Improve Their Therapeutic Efficacy

David García-Bernal1,2†, Mariano García-Arranz2,3†, Rosa M. Yáñez2,4,5†, Rosario Hervás-Salcedo2,4,5, Alfonso Cortés2,6, Maria Fernández-García2,4,5, Mireia Hernando-Rodríguez2,4,5, Óscar Quintana-Bustamante2,4,5, Juan A. Bueren2,4,5, Damián García-Olmo2,3, Jose M. Moraleda1,2, José C. Segovia5,6,5 and Agustín G. Zapata2,7*

1 Hematopoietic Transplant and Cellular Therapy Unit, Medicine Department, Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca, University of Murcia, Murcia, Spain, 2 Spanish Network of Cell Therapy (TerCel), Instituto de Salud Carlos III, Madrid, Spain, 3 Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (IIS-FJD, Autonomous University of Madrid (UAM)), Madrid, Spain, 4 Advanced Therapies Mixed Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz (IIS-FJD, Autonomous University of Madrid (UAM)), Madrid, Spain, 5 Centre for Cytometry and Fluorescence Microscopy, Complutense University, Madrid, Spain, 6 Hematopoietic Innovative Therapies Division, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas and Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain, 7 Department of Cell Biology, Complutense University, Madrid, Spain

Mesenchymal stromal cells (MSCs) currently constitute the most frequently used cell type in advanced therapies with different purposes, most of which are related with inflammatory processes. Although the therapeutic efficacy of these cells has been clearly demonstrated in different disease animal models and in numerous human phase I/II clinical trials, only very few phase III trials using MSCs have demonstrated the expected potential therapeutic benefit. On the other hand, diverse controversial issues on the biology and clinical applications of MSCs, including their specific phenotype, the requirement of an inflammatory environment to induce immunosuppression, the relevance of the cell dose and their administration schedule, the cell delivery route (intravascular/systemic vs. local cell delivery), and the selected cell product (i.e., use of autologous vs. allogeneic MSCs, freshly cultured vs. frozen and thawed MSCs, MSCs vs. MSC-derived extracellular vesicles, etc.) persist. In the current review article, we have addressed these issues with special emphasis in the new approaches to improve the properties and functional capabilities of MSCs after distinct cell bioengineering strategies.

Keywords: MSC bioengineering, MSC homing, MSC immunomodulation, MSC preconditioning, MSC therapeutic efficacy
INTRODUCTION

Mesenchymal Stromal Cells: Lights and Shadows in the Knowledge of Their Mechanisms of Action

Numerous questions on the biology of mesenchymal stromal cells (MSCs), the most promising cell type for cell therapy strategies, remain unknown (Galipeau and Sensebe, 2018). This would explain the variability of both, the reported preclinical and clinical results and the difficulties to establish a general pattern of functioning for these cells. A current survey on the heterogeneity of MSCs, their immunogenicity, routes of delivery and migratory capacity, and principally on the mechanisms governing their immunomodulatory properties needs a substantial revision in order to design protocols for improving their therapeutic capacities, including MSC bioengineering.

MSCs were initially described as colony forming units-fibroblasts (CFU-Fb) capable of differentiating into distinct connective tissue lineages (i.e., osteoblasts, chondroblasts and adipocytes) (Friedenstein et al., 1970; Caplan, 1991; Pittenger et al., 1999). Multiple parameters can affect the therapeutic properties of MSCs including tissue origin (Ketterl et al., 2015), cryopreservation procedure (Oja et al., 2019), culture time and properties of MSCs including tissue origin (Ketterl et al., 2015), media supplementation with different growth factors (von Bahr et al., 2019) can affect substantially the cellular therapeutic properties of MSCs. Therefore, a better knowledge of these cell processes would improve the therapeutic outcomes of MSCs.

Mesenchymal Stromal Cell Immunophenotype and Immunomodulatory Properties

There are no specific markers to characterize the immunophenotype of the MSCs. In humans, MSCs express CD73, CD90, CD105, CD166, CD29, and CD44 that are also present in many other cell types (Pittenger et al., 1999). Negative markers include CD34, CD45, CD14, CD11b, CD79a, CD10, and HLA-DR, except in the presence of IFNγ (Alfaro et al., 2020). In addition, they express numerous cytokine and chemokine receptors as well as distinct Toll-like receptors (TLRs) that play distinct immunomodulatory functions including the inhibition of T cell responses, antigen-presenting cell maturation, cytotoxicity of resting NK cells and differentiation of monocytes to immature dendritic cells (DCs) (Beyth et al., 2005; Jiang et al., 2005; Spaggiari et al., 2006; de Castro et al., 2019). Indeed, MSCs exhibit high plasticity over time and probably related with their origin in different microenvironments (Wilson et al., 2019). This MSC heterogeneity is due, at least in part, to the occurrence of distinct expression profiles (i.e., surface markers, transcriptome and proteome), and functional properties (Phinney et al., 2006; James et al., 2015; Mattar and Bieback, 2015). Some authors have proposed, but not conclusively demonstrated, that induced pluripotent stem cells (iPSCs)-derived MSCs could constitute a more homogeneous cell population (Bloor et al., 2020).

Nevertheless, it is important to clarify more conclusively the relevance of an inflammatory environment for the MSC-mediated immunomodulation. Two recent publications by Naserian and colleagues (Beldi et al., 2020a,b) have provided new and relevant information on the role played by TNF-α signaling in these processes. TNF-α exerts its effects through interaction with two receptors, TNFR1 and TNFR2. Whereas TNFR1 is ubiquitously expressed, TNFR2 expression is restricted to some cell types, including MSCs (Salomon et al., 2018; Yang et al., 2018). Remarkably, TNFR2 signaling results in pro-angiogenic and survival effects, but activation of TNFR1 signaling pathway generally induces apoptosis (Faustman and Davis, 2013). Furthermore, MSCs isolated from TNFR2 KO mice are less efficient in governing immunosuppression, including reduced capability to induce T cell differentiation toward Treg cell lineage (Beldi et al., 2020b).

More recently, extended analysis of these TNF deficient MSCs demonstrated that impeded TNF signaling courses with reduced MSC colony-forming units (CFUs), proliferative rate and expression of diverse MSC cell markers. In addition, these deficient TNF MSCs produce more pro-inflammatory molecules (i.e., TNF-α, IFNγ, IL-6), less IL-10, TGFβ and nitric oxide (NO), and show reduced regenerative capabilities for wound healing, vascular tube formation and neoangiogenesis (Beldi et al., 2020a).

It has been proposed that the therapeutic properties of MSCs depend on the crosstalk of these cells with the host tissues (Ankum et al., 2014; Galleu et al., 2017; de Witte et al., 2018; Galipeau and Sensebe, 2018), as suggested by the mechanisms which control their immunoregulatory properties and the status of pre-sensitization of host (Avivar-Valderas et al., 2019). During acute inflammation, MSC activation is critical for the production of immunoregulatory factors, in contrast with non-activated MSCs, which do not exhibit a significant production of these molecules. In acute inflammatory conditions, activated T cells secrete pro-inflammatory cytokines (i.e., IFNγ, TNF-α, IL-1, or IL-17), that activate MSCs initiating the modulation of immune responses by releasing anti-inflammatory molecules, such as prostaglandin E2 (PGE2), IL-10, HLA-G, indoleamine-2,3-dioxygenase (IDO), hepatic growth factor (HGF), TGFβ, NO, galectins, semaphorin-3A or heme-oxigenase (HO) as well as multiple chemokines (i.e., CXCL10, CXCL11, CXCL12, and CXCL19) (Jimenez-Puerta et al., 2020).

In general terms, activated MSCs in an inflammatory microenvironment block or largely inhibit activation of the complement system, neutrophils, T cells, B cells and NK cells. MSCs stimulate functional maturation of anti-inflammatory type 2 macrophages, regulatory DCs and T regulatory cells as well (Saparov et al., 2016; Wang et al., 2018, 2019; Jimenez-Puerta et al., 2020). Therefore, TLRs and numerous immunomodulatory factors secreted or expressed by MSCs are orchestrated to function together. Indeed, it has not been possible to identify one single mechanism responsible for the immunomodulatory properties of MSCs and distinct factors seem to act, coordinately and/or sequentially in the blockade of the immune system (Ferreira et al., 2018). On the other hand, PGE2 production largely depends on IL-10 signaling.
and MSCs stimulated by kinuretin through aryl-hydrocarbon receptors (AhR) show an increased production of iNOS, IDO and PGE2 (Jiang et al., 2005; Wang et al., 2018; de Castro et al., 2019). Moreover, low levels of TGFβ correlate with reduced IDO (Xu et al., 2014), and TNF-stimulated gene 6 (TSG6), that inhibit neutrophilia by blocking CXCL8-mediated chemotaxis, is regulated by AhR and IDO (Wang et al., 2018). Moreover, TLR2 activation induces galectin-3 production, increasing its capacity to suppress T cell activation (Sioud et al., 2010). However, effects mediated through TLR3 and TLR4 are controversial, although it is generally assumed that TLR3 signaling induces an anti-inflammatory MSC profile (MSC-2), while TLR4 signals promote pro-inflammatory MSCs (Shammam et al., 2020). Importantly, and apart from their immunomodulatory properties, other studies have found that MSCs also possess robust anti-bacterial properties through secretion of a variety of anti-microbial peptides and/or proteins such as lipocalin-2, IL-37, hepcidin, keratinocyte growth factor and β-defensin-2 which has led to MSCs being considered as a therapeutic option for sepsis and septic shock (Krasnodembskaya et al., 2010; Gupta et al., 2012; Alcayaga-Miranda et al., 2015; Sung et al., 2016).

The key role played by Treg cells for governing MSC-mediated immunosuppression deserves further, more extensive analysis. MSCs induce Treg cell differentiation by increasing production of PGE2, TGFβ and IL-10. In addition, they increase Treg cell proliferation via TLR2 and TLR3 signaling, thrombospondin, IL-2 and TNF-α through activation of Stat5 that increases CD39 and CD73 expression, both molecules involved in the adenosine production necessary for Treg cell function (de Castro et al., 2019). On the other hand, as previously indicated, a close relationship has been established between TNFR2 expression and Treg cell function (Salomon et al., 2018; Yang et al., 2018; Naserian et al., 2020). Remarkably, Treg lymphocytes express TNFR2 which is directly related to their immunosuppressive effects (Leclerc et al., 2016; Naserian et al., 2020).

On the other hand, some reports suggest that systemically injected MSCs have immunosuppressive properties because they are entrapped in the lung microvasculature, die by apoptosis and are engulfed by local macrophages that become type 2 macrophages which secrete IL-10 and arginase immunosuppressive factors (Anderson et al., 2013; Braza et al., 2016). Engulfed MSCs appear mainly in non-classical Ly6Clo monocytes that polarize toward CD14+CD16+CD296+ monocytes, an intermediate phenotype with anti-inflammatory properties that produces IL-10 and express PDL-1. In addition, these primed monocytes that engulfed MSCs induce CD4+CD25high Treg cell formation (Weiss and Dahlke, 2019).

These results indirectly support that apoptotic, metabolically inert or even fragmented MSCs would have the same immunomodulatory properties as living MSCs (Chang et al., 2012; Galleu et al., 2017; Weiss and Dahlke, 2019). Therefore, the viability of MSCs would not be a pre-requisite for some of their exerted immunomodulatory effects (Weiss and Dahlke, 2019). In this respect, Thum and colleagues pointed out that the apoptosis of MSCs is caused by modulation of both innate and adaptive immunity (Thum et al., 2005) and further studies support this idea. Apoptotic MSCs exhibited an immunosuppressive behavior in a Th2-type inflammatory model, inducing IDO production in host phagocytic cells (Galleu et al., 2017), and supernatants of cultured macrophages that engulfed MSCs improved the survival of hypoxic cardiomyocytes (Lu et al., 2013). Remarkably, systemic administration of apoptotic adipose tissue-derived MSCs provide better therapeutic results than the treatment with living MSCs in a cecum ligation and puncture-induced sepsis model (Sung et al., 2013). On the other hand, MSCs heated for 30 min at 50°C that provokes an irreversible blockade of cell metabolism but maintains the cell integrity, were able to reduce the inflammatory response in mice receiving LPS by a significant reduction of the serum levels of IFNγ and increased production of IL-10 (Luk et al., 2016). Also, normal MSCs and metabolically inactive MSCs showed similar effects on monocyte function with a significant reduction of TNF-α production in response to LPS (Jiang et al., 2005). By contrast, the intrapulmonary administration of apoptotic MSCs did not increase survival or reduced the severity of endotoxin-induced acute lung injury (Gupta et al., 2007), in contrast with several studies demonstrating the significant positive effect of living MSCs in the reduction of sepsis in different experimental models (Gupta et al., 2007; Johnson et al., 2017).

MESENCHYMAL Stromal Cell Manufacturing

MSC manufacturing for clinical use has been regulated worldwide for over a decade in an attempt of protecting potential users. Production of cell medicaments with protocols accepted by regulatory agencies under GMP conditions generates a cellular product with specific properties and a high level of safety. Autologous MSC manufacture was the first step and these cells are currently used in the majority of clinical trials and treatments; however, this procedure has disadvantages such as the time required to obtain an adequate number of cells from older or fragile patients, or the difficulty of growing MSCs in vitro from patients with different pathologies. For this reason, cryopreservation of cells has been frequently used to allow delayed treatment or for allogeneic donors; although cryopreservation is not an innocuous process for cells.

Cryopreservation has interesting benefits in clinical practices and is mandatory for MSC banking, but its effects on MSC biology are controversial. While some authors have discussed that the cryopreservation process reduces MSC potency, other studies have found no significant influence on their immunomodulatory properties (Cruz et al., 2015; Luetzkendorf et al., 2015). Two freezing steps with, at least, one preceding cell culture passage before freezing do not seem to affect the essential biological parameters of MSCs (i.e., cell yield, growth kinetics and population doubling number), but ≥4 freezing steps could accelerate the senescence of cultured MSCs. In addition, the immunosuppressive potential of frozen and thawed MSCs, independently of the number of freezing steps, is reduced by about 50% as compared to freshly cultured MSCs, but definitively...
do not abolish the process, even after long periods (>10 months) of cryopreservation (Klinker et al., 2017; Oja et al., 2019; Giri and Galipeau, 2020). Moreover, a variety of methods for long-term storage of MSCs using different formulations of cryopreservation media or different procedures for MSC freezing and thawing may subsequently greatly affect the MSC potency (Ding et al., 2010; Liu et al., 2010; Moll et al., 2014a; Miyagi-Shiohira et al., 2015; Rogulska et al., 2019). Therefore, the improvement of the cryopreservation conditions to ensure the intrinsic biological properties of MSCs needs further investigation in order to extend the utility of MSC banking for subsequent cell therapy uses.

On the other hand, the production of a sufficient number of MSCs by in vitro expansion for obtaining a clinical dose may have some impact on the native properties of the MSCs. Although MSCs can be growth up to 20 passages, these long-term cultured MSCs have shown senescence genes up-regulation, morphologic changes, decreased differentiation potential, chemokine receptor down-regulation, telomere length shortening and decreased immunosuppressive properties compared to short-term cultured counterparts (Jiang et al., 2002; Rombouts and Ploemacher, 2003; Honczarenko et al., 2006; Izadpanah et al., 2008; Li et al., 2012; Lian et al., 2016). Accordingly, the establishment of universal protocols for maintenance, banking and culture of MSCs would be welcome.

ALLOGENEIC OR AUTOLOGOUS MESENCHYMAL STROMAL CELLS FOR THERAPEUTIC USAGE

A second controversial issue is whether allogeneic better than autologous MSCs would be used clinically. Indeed, both preclinical studies and clinical trials show an increasing use of allogeneic MSCs. Autologous MSC transplantation has some limitations. Firstly, the high cost of cell preparation just for a single recipient. Moreover, it is difficult to obtain a clinical dose of MSCs from some patients. For example, MSCs isolated from elder donors have decreased proliferation, less differentiation, and less regenerative potential, subsequently leading to ineffective treatments (Maredziak et al., 2016). By contrast, it is evident that the use of allogeneic vs. autologous MSCs for cell therapy has clear advantages (Hare et al., 2012; Zhang et al., 2015). Allogeneic MSCs from young healthy donors are an optimal choice to solve this problem. In addition, the expansion of autologous MSCs to obtain a clinical dose is time-dependent, making this therapeutic approach difficult for the early treatment of diseases in acute phase (e.g., COVID-19, brain stroke, septic shock or myocardial infarction). However, allogeneic MSCs, cryopreserved and stored once obtained, can be readily available, quickly thawed, and immediately administered to the patient who requires them. For all these reasons, cryopreserved allogeneic MSCs are a promising therapeutic alternative to autologous MSCs with multiple advantages in terms of time, cost of production and quality assurance. Importantly, allogeneic MSCs from pooled mononuclear cells of multiple third-party donors have been reported to exhibit decreased heterogeneity and to exert significantly higher immunosuppressive potential than those obtained from individual donors (Kuci et al., 2016).

However, this proposal leads to the unsolved question of the MSC immunogenicity. It is well known that there is immune activation of host cytotoxicity mediated by complement, NK cells and/or cytotoxic T cells (Noone et al., 2013; Ankrum et al., 2014; Berglund et al., 2017; Kot et al., 2019). In fact, syngeneic MSCs persist for more than 200 days, whereas allogeneic cells rapidly disappear (Eliopoulos et al., 2005). Although, low or null immunogenicity for allogeneic MSCs has been claimed (Le Blanc et al., 2003; Escacena et al., 2015). Nevertheless, recent in vivo and in vitro evidence suggests that MSCs generate both innate and adaptive host immune responses (Caplan et al., 2019). However, anti-MSC responses are lower than those against other allogeneic cells are (Khan and Newsome, 2019), perhaps because MSCs do not express MHC class II antigens or co-stimulatory molecules. Therefore, the balance between their immunogenicity and the release of immunosuppressive factors, highly dependent on the local microenvironment, determines the MSC behavior (Khan and Newsome, 2019). Even more, this cytoxic activity is important for MSC-mediated immunosuppression because it results in phagocytosis of apoptotic cells and then macrophage polarization (Galleu et al., 2017; de Witte et al., 2018). Thus, reduction of the activity of host immune system could diminish the efficiency of MSCs (Caplan et al., 2019).

Accordingly, the study of HLA matching between donor MSCs and recipient of these cells is being recently proposed (Avivar-Valderas et al., 2019). On a phase III clinical trial for the treatment of complex perianal fistulous pathology in patients with Crohn’s disease, the authors carried out a study on the immunological responses and MSC efficacy taking into account the haplotypes of the donor cells and the recipient concluding that an HLA-screening to the donor MSCs would be performed to limit the humoral response between donor and recipient.

DELIVERY OF MESENCHYMAL STROMAL CELLS

There is no consensus on the best method for MSC delivery (Caplan et al., 2019). Intramuscular delivery is a safe and simple method, but its efficiency is frequently low (Jahromi et al., 2019). In some organs, in situ direct injection is almost mandatory but may impede interactions between MSCs and host cells, particularly in lungs and spleen, thus limiting their therapeutic activity. In addition, delivery of a high number of cells could induce important cell damage, including high cell mortality by trauma, hypoxia or NK cell-mediated MSC apoptosis. On the contrary, systemic infusion of MSCs allows interactions with host cells and tissues but needs an adequate biodistribution and homing to affected tissues, which is sometimes limited. Intra-arteriolar delivery would be the most efficient method but also can be potentially harmful because MSCs mechanically entrap in the microvasculature elsewhere (Toma et al., 2009). The most frequently used method is the systemic delivery by intravenous injection but, particularly in rodents and in lesser
extent in humans, results in a high number of entrapped MSCs in lung capillaries that limit the number of cells reaching target organs and increase the risk of thromboembolism (Scarfe et al., 2018; Coppin et al., 2019). Although there are only a few clinical trials reporting MSC-associated thrombotic events (Jung et al., 2013; Wu et al., 2017), MSC delivery triggers the activation of the complement system and the coagulation cascade inducing the so called “Instant Blood-Mediated Inflammatory Reaction” (IBMIR) (Moll et al., 2012, 2019). MSCs express the pro-coagulant tissue factor (CD142) (Drake et al., 1989), and MSC systemic injection significantly increases C3a and sC5b-9 levels and activation of the thrombin-anti-thrombin complex, inducing a drop in platelet numbers and increased values of D-dimer (Moll et al., 2015). These results remark the relevance of monitoring MSC pro-coagulant activity after their systemic infusion (Caplan et al., 2019). On the other hand, release of complement activation factors after exposure to MSCs could modulate their immunomodulatory and chemotactic activity (Schraüfstatter et al., 2009; Moll et al., 2011), and protocols to avoid or attenuate complement-mediated cell damage would improve the efficiency of MSC-based therapies (Moll et al., 2016).

**MESENCHYMAL STROMAL CELL HOMING**

Similar to leukocytes and hematopoietic stem cells, MSCs must undergo a multistep process to extravasate from the circulating blood and migrate through the vessel walls to the damaged tissues. This process includes various sequential steps: (1) an initial decelerative tethering followed by direct rolling contacts with endothelial cells; (2) activation of integrins (mainly induced by chemokines); (3) integrin-dependent firm adhesion to endothelial cells; (4) transendothelial migration; and (5) interstitial migration toward the injured tissue (Nitzsche et al., 2017). However, MSC homing to the damaged organs is very inefficient, and only a small proportion of cells reach target tissues (Devine et al., 2003). A restricted repertoire of functional homing and chemokine receptors exhibited by MSCs could be reason for this inefficiency (Honczarenko et al., 2006; Chamberlain et al., 2008). Among them, MSCs express neither the sialofucosylated glycoforms of CD44 nor P-selectin glycoprotein ligand-1 (PSGL-1). These molecules, called hematopoietic cell E-/L-selectin ligand (HCELL) and cutaneous lymphocyte antigen (CLA), respectively, contain the sialyl Lewis X (sLeX) moiety that mediate migration to E-selectin-bearing endothelial beds in sites of inflammation (Sackstein et al., 2008; Sackstein, 2009). In addition, the response of MSCs to CXCL12 gradients is controversial because it has been reported that they do not express its receptor, CXCR4 (Ullah et al., 2019). By contrast, MSCs extravasation is mediated by the expression of FGF receptors that interact with bFGF on endothelial cells mediating galectin-1-dependent adhesion to P-selectin (Langer et al., 2009). Then, MSCs send out filopodia and cross the intraluminal space with the concourse of metalloproteinases and the development of a front cell pole through their intracellular adaptor FRONT and the chemokine receptor CCR2 (Zachar et al., 2016). But this mechanism of extravasation is less effective.

On the other hand, it has been found that in vitro prolonged expansion of MSCs in culture produces a down-regulation of a variety of homing molecules including chemokine receptors, such as CCR1, CCR7, CCR9, CXCR5, and CXCR6, thus lacking the chemotactic response to these chemokines (Rombouts and Ploemacher, 2003; Honczarenko et al., 2006). Accordingly, attempts for improving MSC homing are complex and require further optimization. Some of them have focused on introducing modifications in the expression of different homing molecules on migrating MSCs through a wide variety of genetic, enzymatic or ligand conjugation approaches. Enzymatic treatment of MSCs by α(1,3)-exofucosylation of the CD44 receptor with either stereospecific fucosyltransferase VI or fucosyltransferase VII in presence of its substrate GDP-fucose, or by fucosyltransferase VI gene transfection, has been shown to engender the potent E-selectin ligand HCELL on the MSC surface. This transient modification increases efficiently the in vivo tethering and rolling contacts on E-selectin-expressing endothelial beds in bone marrow microvasculature and in inflamed tissues (Sackstein et al., 2008; Abdi et al., 2015; Dykstra et al., 2016; Chou et al., 2017). Remarkably, recent findings have shown that exofucosylated MSCs display an altered secretome characterized by an augmented expression of anti-inflammatory molecules, leading to higher MSC immunosuppressive properties, as well as increased migration ability toward some pro-inflammatory chemokines such as CCL5, CCL20 and CXCL16 (Garcia-Bernal et al., 2020). Other authors reported that covalent binding of sLeX to the MSC surface through a biotin-streptavidin bridge, by conjugation of E-selectin-targeting peptide on the MSC membrane or by mRNA transfection to overexpress PSGL-1 and sLeX on MSCs resulted in an augmented rolling behavior on P- and E-selectin-coated surfaces and on inflamed vascular endothelium in vivo (Sarkar et al., 2008; Cheng et al., 2012; Levy et al., 2013). Lo et al. fused the first 19 aminoacids of PSGL-1 to human IgG and, after overexpression of this construct on HEK293T cells (a cell line with endogenous fucosyltransferase VII expression), they coupled this fusion protein to the MSC surface using palmitated protein G (PPG), leading to an increased rolling on P- and E-selectin-coated surfaces under hydrodynamic flow (Lo et al., 2013). By contrast, Ko et al. coated MSCs with PPG and anti-ICAM-1 antibodies, thus improving its ability to adhere to this endothelial ligand (Ko et al., 2009).

Engineering approaches for improving other MSC functional capacities, that will be described below, have been used for increasing MSC homing. Genetic modification by mRNA transfection is highly efficient and non-toxic to MSC as well as compatible with ectopic co-expression of multiple mRNAs at the same time (Kormann et al., 2011; Hamann et al., 2019). Using these types of strategies, Liao et al. tested the therapeutic capacity of engineered MSCs expressing PSGL-1, sLeX, and IL-10 via mRNA transfection in a mouse model of experimental autoimmune encephalomyelitis observing a decreased infiltration of immunocompetent cells into the white matter of the spinal cord (Liao et al., 2016). More recently, Hervás-Salcedo et al. have shown the improved therapeutic
The administration of IL-10-transduced bone marrow allogeneic MSCs attenuated the severity of acute graft-vs.-host disease in a murine model, while unmodified MSCs were not able to control the disease progression (Min et al., 2007). Different studies found that serum levels of IL-10 in rheumatoid arthritis-suffering patients was lower than that found in healthy people, but some pro-inflammatory factors, such as IL-1\( \alpha \), IL-17, IL-1\( \beta \) and TNF-\( \alpha \), were higher (Baek et al., 2012; Shoda et al., 2017). Using an adenovirus system to overexpress IL-10, Tian et al. analyzed the therapeutic effect of IL-10-overexpressing bone marrow-derived MSCs (IL-10-BMMSCs) in a collagen-induced rheumatoid arthritis rat model. After 4 and 8 weeks of treatment

**ENGINEERING MESENCHYMAL STEM CELLs FOR ENHANCING THEIR THERAPEUTICAL PROPERTIES**

The myriad of processes that governs the biology and function of MSCs makes difficult to manipulate them for improving their therapeutic possibilities. Different experimental approaches have engineered MSCs (i.e., MSCs-2.0) aimed to enhance their therapeutic efficacy compared to native MSCs and have been tested in several preclinical models of a variety of diseases. MSCs have been mainly modified to increase their survival, retention, migration capacities and growth factor production, principally through genetic modifications, usually achieved by means of viral vectors but also using non-viral methods. Standard protocols can reach high levels of transduction without affecting the lineage differentiation or the intrinsic properties of MSCs. Constitutive rather transient transformation provides the best therapeutic effects (Lin et al., 2011). The most common vectors used to modify MSCs are retrovirus, lentivirus, adeno-virus and adeno-associated virus (AAV) (Sage et al., 2016). Among the non-viral approaches mRNA lipofectamine-mediated transfection, PEGylated DNA template nanocomposite system, biotinylated MSC, sperm pullulan, hyper-branched polyamidoamine and jetPEI-mediated transfection have been used (Pawitan et al., 2020).

On the other hand, several studies found that the incorporation of anti-inflammatory genes such as IL-10, HGF, IDO and FoxP3 could improve the therapeutic potential of MSCs. The overexpression of other factors including VEGF, BMP2, osteogenic molecules (i.e., TGF\( \beta \), Cbfa-1, and Osterix), or molecules involved in homing (CXCR4 and CXCL12), etc. have been shown to enhance the MSC capacities (Pawitan et al., 2020). Particularly, enhanced IL-10 production has been intensively tested. IL-10 is a strong anti-inflammatory cytokine produced by monocytes/macrophages, Th2 lymphocytes and regulatory T cells. IL-10 inhibits the production of pro-inflammatory cytokines by Th1 lymphocytes and improves survival, proliferation and antibody production of B-lymphocytes. Therefore, enhanced IL-10 expression could represent a promising therapeutic approach for diverse pathologies in which immunosuppression is needed (Grutz, 2005; Mosser and Zhang, 2008).

As previously indicated, triple-transfected PSGL-1/sLeX/IL-10MSCs injected in an mouse model of local inflammation in the ear, induced a transient increase in the levels of IL-10 in the inflamed ear, and mediated a superior anti-inflammatory effect in vivo compared to wild type MSCs (Levy et al., 2013). These results are also supported by the cited above study in which the authors demonstrated the enhanced anti-inflammatory potential of human AdMSCs transfected with a single mRNA encoding for the receptor CXCR4 and IL-10 (Hervas-Salcedo et al., 2021).

The administration of IL-10-transduced bone marrow allogeneic MSCs attenuated the severity of acute graft-vs.-host disease in a murine model, while unmodified MSCs were not able to control the disease progression (Min et al., 2007). Different studies found that serum levels of IL-10 in rheumatoid arthritis-suffering patients was lower than that found in healthy people, but some pro-inflammatory factors, such as IL-1\( \beta \) and TNF-\( \alpha \), were higher (Baek et al., 2012; Shoda et al., 2017). Using an adenovirus system to overexpress IL-10, Tian et al. analyzed the therapeutic effect of IL-10-overexpressing bone marrow-derived MSCs (IL-10-BMMSCs) in a collagen-induced rheumatoid arthritis rat model. After 4 and 8 weeks of treatment
IL-10-BMMSCs receiving rats improved significantly their clinical condition. The repairing rate of osteoarticular cartilage and the inhibition of synovial proliferation were higher in the IL-10-BMMSCs group than in the unmodified counterparts. Accordingly, serum levels of the pro-inflammatory cytokines IL-17, IL-1β, and TNF-α were also lower (Tian et al., 2019). In a model of *Escherichia coli* pneunompepsis in rats, IL-10 overexpression in umbilical cord derived-MSCs (UC-MSCs) enhanced the capacity to attenuate lung injury compared to unmodified UC-MSCs, due to increased macrophage phagocytosis and killing of *E. coli* (Jerkic et al., 2019). Recently, Zhao et al. also found that MSCs transmited with a recombiant plasmid IL10-PEGFP-C1 were able to suppress the pancreatic cancer cell proliferation *in vitro* and to reduce the growth of tumor xenograft *in vivo*, prolonging the mouse survival, inhibiting tumor angiogenesis and reducing blood levels of TNF-α and IL-6 in mice with tumors (Zhao et al., 2020).

IL-10 has been also claimed to play a neuroprotective and vasculoprotective role in cerebrovascular disorders by attenuating pro-inflammatory signals and by upregulating anti-apoptotic proteins (Zhou et al., 2009). Nakajima et al. investigated the therapeutic benefit of adeno-associated virus (AAV)-mediated IL-10 overexpression in MSCs transplanted during the acute phase of ischemic stroke in Sprague-Dawley rats. MSC-IL10 grafting significantly inhibited microglial activation and pro-inflammatory cytokine expression. Moreover, overexpression of IL-10 suppressed neuronal degeneration and improved survival of engrafted MSCs in the ischemic hemisphere (Nakajima et al., 2017).

In a rat model of myocardial infarction, Meng et al. transduced bone marrow-derived MSCs using an adenoval vector to secrete IL-10 (Ad.IL-10—MSCs). These modified MSCs were transplanted into injured hearts resulting in reduced myocardial infarcted area, cardiac impairment and cell apoptosis. Even, genome-editing technology using transcription activator-like effector nucleases (TALENs) has been used to generate functionally improved amniotic MSCs (Meng et al., 2019). The administration of these IL-10 gene-edited amniotic MSCs in an acute myocardial infarction mouse model showed higher anti-inflammatory properties and enhanced recovery of heart function, also providing a favorable environment for neovascularization.

On the other hand, FoxP3-expressing MSCs prevent rejection of allogeneic grafted liver, increasing the median survival time of treated mice by increasing the numbers of Treg cells and the PD-L1 expression on MSCs (Qi et al., 2015). In other studies, HGF-expressing MSCs exhibited enhanced regenerative and anti-apoptotic effects in murine models of radiation-induced toxicity (Zhang J. et al., 2014; Wang et al., 2015), and induction of early immunosuppression in mice undergoing rheumatoid arthritis (Dong et al., 2020). Bcl-2 is also a robust anti-apoptotic protein, which has been overexpressed in MSCs. These cells ameliorated myocardial infarction damage in mice by increasing cell engraftment and VEGF-mediated neovascular formation (Li et al., 2007). Other factors overproduced by MSCs (i.e., lipocalin-2) indirectly improved their therapeutic capacity inducing production of regenerative factors such as HGF, IGF, FGF, and VEGF (Roudkenar et al., 2018). In fact, MSCs can secrete both angiogenic and anti-angiogenic factors in response to signals from microenvironment. For example, MSCs respond to TGFβ/EGF receptor by increasing VEGF production (De Luca et al., 2011). On the other hand, VEGF signaling pathway is defective in TNFFR2 KO mice (Luo et al., 2006), and a correlation between TNFFR2 expression by MSCs and NO production, that directly induces VEGF, has been recently established (Beldi et al., 2020a). Previously, it has been found that VEGF production by TNF-α-primed human bone marrow MSCs was TNFR2 dependent (Crisostomo et al., 2008; Zhang A. et al., 2010).

As above mentioned, CXCL12/CXCR4 signaling pathway is important for in vivo MSC homing to injured sites but also increase VEGF expression, thus contributing to neangiogenesis. Accordingly, CXCL12-secreting MSCs have improved wound healing, dermal fibroblast migration and new blood vessel formation (Nakamura et al., 2013), whereas CXCR4-overexpressing MSCs improved the outcome of myocardial infarction by increasing cell engraftment and angiogenesis and reducing myocardial remodeling (Huang et al., 2010; Zhang D. et al., 2010). Obviously, effects mediated by VEGF-overexpressing MSCs are related to the potent pro-angiogenic capacity of this molecule that improves the blood flow and the heart function in preclinical assays of critical limb ischemia (Beegle et al., 2016) and myocardial infarction (Zhu et al., 2012), respectively.

MSC overexpressing genes involved in osteogenesis, particularly BMP2 have been repeatedly tested in several types of bone defects, improving the bone healing (Chang et al., 2003, 2004, 2010; Tsuchida et al., 2003; Jiang et al., 2009; Zhao et al., 2010). Sometimes, BMP2 and VEGF overexpression have been combined. In these cases, VEGF promotes blood vessel neoformation that favors BMP2-mediated osteogenesis (Lin et al., 2010, 2011, 2012, 2015; Fu et al., 2015).

Engineered MSCs have been also used as anti-tumor therapeutic agents alone or in conjunction with chemotherapeutic drugs (Pawitan et al., 2020). Three strategies have been used: (i) to insert suicide genes that transform non-toxic pro-drugs into cytotoxic molecules; (ii) to use MSCs as vehicles to transport cytokines for enhancing in vivo antitumoral immunity or (iii) as agents to kill directly the tumor cells. Several genes encoding for “suicide proteins” have been used in anti-tumoral therapies, including cytosine deaminase, thymidilate kinase from either herpes simple or SV40 viruses, and cytochrome P450 reductase. In general, MSCs are resistant to these agents, particularly to alkylating agents, although evidence on the effects mediated by nucleoside analogs is scarce. IL-12 (Gao et al., 2010), IFNγ (Seo et al., 2011), and TNF-α (Tycikova et al., 2015) have been overexpressed in engineered MSCs to enhance anti-tumoral immune responses. Another tested strategy is based on the use of MSCs to deliver pro-apoptotic agents to tumor cells. The most frequently used is the overexpression of TNF-related apoptosis inducing ligand (TRAIL), a transmembrane protein that binds to death domain-containing receptors that selectively trigger apoptotic of cancer cells (Luetzkendorf et al., 2010). Other approaches include engineered MSCs to release different anti-angiogenic factors.
HIF-1α (Zhang W. et al., 2014). Numerous studies confirm hypoxia as a preconditioning factor to MSCs cultured in normoxia with 21% oxygen. Indeed, and enhanced their chondrogenic differentiation compared maintained their stemness capacity, increased proliferation rate in vitro during the maintain the stemness and the proliferative capacities of MSCs their physiologic conditions. Thus, hypoxia could contribute to tissue derived-MSCs and colony forming unit efficiency was tissue derived-MSCs were maintained under hypoxic conditions. et al. showed that immunosuppressive properties of adipose promoters such as VEGF and angiotensin (Imtiyaz and Simon, 2010; Ahluwalia and Tarnawski, 2012). Roemeling-van Rhijn et al. investigated the in vivo therapeutic potential of hypoxic-cultured MSCs in a mouse model of streptozotocin-induced insulinitis and hyperglycemia compared to MSCs cultured in normoxic conditions. Either hypoxic-cultured or normoxic-cultured MSCs were injected into this mouse model. Both groups of animals had higher pancreas insulin content compared to untreated control group, but the hypoxic-cultured MSC group had lower fasting blood glucose and improved oral glucose tolerance compared to untreated mice. The authors concluded that hypoxic preconditioning potentiates MSCs ability to protect against hyperglycemia in vivo (Schive et al., 2017).

Alternatively, 3D MSC cultures based on the different conditions of cultures vs. those of two-dimensional (2D) cultures constitute another way for improving the biological and therapeutic properties of MSCs. In fact, 3D MSC cultures reflect better the natural physiological environment than the 2D cultures. Thus, the use of 3D MSC cultures could mimic better the physiologic state of MSCs in their specific resident tissues and influence their paracrine mechanisms. The 3D MSC cultures are based on MSC spheroids encapsulated with various types of scaffolds such as hydrogels, polymers, hydrophilic glass fibers and electrospun silk fibroin meshes. Other approaches that are not based on the use of scaffolds include magnetic levitation, hanging drop microplates or ultralow attachment spheroid microplates (Langhans, 2018; Millan-Rivero et al., 2019; Sankar et al., 2019). The spheroid 3D cultures create a microenvironment in which inner layers are exposed to lower levels of oxygen and nutrients, resembling to a hypoxic environment that affects notably the MSC behavior. Compared to 2D cultures, 3D MSC cultures have shown an augmented secretion of molecules with paracrine function (i.e., cytokines, chemokines, and growth factors), better anti-oxidative and anti-apoptotic functions and higher production of extracellular matrix components (Cushing and Anseth, 2007; Sun et al., 2018; Mukherjee et al., 2020), as well as improved therapeutic effects in some preclinical models such as corneal or skin wound healing (Carter et al., 2019; Millan-Rivero et al., 2019).

This accumulating preclinical evidence on the promising potential of MSC-based cell therapy in the treatment of multiple diseases has allowed its translation to the clinical practice, having been launched to date more than 1,000 clinical trials. However, clinical trials based on the use of engineered MSCs are still very scarce, and only a few studies, mainly phase I and phase II/II, have
been implemented to evaluate “MSCs-2.0” safety and efficacy in a variety of pathologic conditions summarized in Table 1, and their results are eagerly awaited.

On the other hand, in the last years, several studies have emphasized the presumptive relevance of the MSC secretome as a better way of treatment than the own cells for their clinical application (Poltavtseva et al., 2019), although reported results are frequently contradictory and the clinical assays using total secretome or extracellular vesicles (EVs) are limited. On the other hand, despite the difficulties for a conclusive definition of their phenotype, content and physiological function, EVs present some advantages, such as low immunogenicity, stability during extended storage and protection of their content (Kusuma et al., 2017). The term “secretome” includes diverse soluble molecules, such as growth factors, cytokines, immunomodulatory molecules and the named EVs (Kusuma et al., 2017). EVs are a heterogeneous population of lipid-bilayer vesicles that contain biologically active biomolecules such as lipids, proteins, single-stranded DNA and different types of RNAs (Bister et al., 2020; Watanabe et al., 2021). They include small exosomes (40–120 nm) originated from multivesicular bodies of the endosomal compartment that are secreted by exocytosis, and larger microvesicles (200–1,000 nm) that bud directly from the plasma membrane (Kusuma et al., 2017).

Moreover, MSCs derived from different sources produce some specific factors: adipose tissue-derived MSCs secrete more IGF-1, VEGF, and IL-8 than those from the bone marrow, whereas MSCs from the umbilical cord Wharton’s jelly secrete the highest amounts of immunomodulatory molecules such as IL-6, IL-7, IL-10, PDGF-A, and TGFβ2. On the contrary, adipose tissue-derived MSCs produce more extracellular matrix components such as collagen-1 and -2, and metalloproteinases (Amable et al., 2014), and a common group of secreted molecules including chemokines (CCL2 and CCL5), growth factors (bFGF and IGF-1), cytokines (IL-6 and TGFβ) and others (TNFR-I) (Wang et al., 2019). However, not only soluble factors can be secreted by MSCs. Remarkably, mitochondria can be transferred between cells via tunneling nanotubes, cell fusion or contained into secreted EVs (Torralba et al., 2016; Ferrone et al., 2017). Therefore, the secretome recapitulates many of the properties described for MSC themselves (Ferreira et al., 2018), including immunomodulation (Teng et al., 2015), inhibition of both apoptosis and fibrosis (Li et al., 2013; Teixeira et al., 2015), induction of vascularization (Teng et al., 2015) and promotion of tissue remodeling and cell recruitment (Chen et al., 2014). Furthermore, EVs derived from MSCs activated or not with IFNy exhibit distinct capacities. Both EVs reduce the frequency of CD14+ monocytes, but those derived from IFNy-treated MSCs also exhibit higher expression levels of the classical costimulatory molecules (Goncalves et al., 2017).

Although the number of clinical trials using MSC-derived EVs for the treatment of different pathologies is still very limited (see Table 2) and their conclusions unpublished, numerous preclinical studies support their functional capabilities. Different lung injuries improve after treatment with MSC-derived EVs.

### Table 1 | Clinical trials involving engineered MSCs in Clinicaltrials.gov website.

| Study title | MSC source | Modification | Pathology | Phase | Identifier |
|-------------|------------|--------------|-----------|-------|------------|
| MV-NIS infected MSCs for treating patients with recurrent ovarian, primary peritoneal or fallopian tube cancer | Adipose tissue | MSCs transduced with Edmonston’s strain measles virus (MV) genetically engineered to produce sodium iodine symporter (NIS) | Recurrent ovarian, primary peritoneal or fallopian tube carcinoma or adenocarcinoma | Phase I/II | NCT02068794 |
| Genetically Modified MSC Therapy Against Head and Neck Cancer (Gx-051) | N/A (Gx-051) | MSCs expressing modified interleukin-12 (MSCs/IL-12M) | Head and neck neoplasm | Phase I | NCT02079324 |
| Osteogenic effects in human MSCs enhanced by Wnt signaling | Bone marrow | Viral administration of Wnt3a-transduced MSCs with hydroxyapatite nanoparticles | Severe pulmonary emphysema | Phase I/II | NCT01849159 |
| Efficacy and safety of allogeneic MSCs of bone marrow, cultured under hypoxia in the treatment of patients with severe pulmonary emphysema | Bone marrow | MSCs cultured under hypoxic conditions | Chronic pulmonary disease | Phase II | NCT04042844 |
| A single dose of BRTX-100 for patients with chronic lumbar disc disease | Bone marrow (BRTX-100) | Hypoxic-cultured bone marrow mononuclear cells highly enriched in MSCs from autologous bone marrow with autologous platelet lysate | Chronic lumbar disc disease | Phase II | NCT04042844 |
| Intravenous infusion of fucosylated bone marrow MSCs in patients with osteoporosis | Bone marrow | Enzymatic exofucosylation by fucosyltransferase VIII and GDP-fucose treatment | Osteoporosis with low impact bone fractures | Phase I | NCT02566655 |

N/A, data not available. Fast track designation of commercial cell therapy products is also indicated.
| Study title                                                                 | MSC-ECVs source | Pathology                                                   | Phase       | Identifier       |
|---------------------------------------------------------------------------|-----------------|------------------------------------------------------------|-------------|-----------------|
| Exosomes of MSCs for multiple organ dysfunction syndrome after surgical repair of acute type A aortic dissection | N/A             | Surgical repair of acute type A aortic dissection          | Not applicable | NCT04356300    |
| MSC-exos promote healing of macular holes                                 | Umbilical cord  | Large and refractory macular holes                         | Phase I     | NCT03437759     |
| Effect of UMSCs derived exosomes on dry eye in patients with cGvHD        | Umbilical cord  | Dry eye symptoms in chronic GvHD                           | Phase I/II   | NCT04213248     |
| Safety and efficacy evaluation of allogeneic adipose MSC-exos in patients with Alzheimer’s disease | Adipose tissue  | Mild/moderate dementia associated to Alzheimer’s disease   | Phase I/II   | NCT04388982     |
| Effect of microvesicles and exosomes therapy on B-cell mass in type I diabetes mellitus | Umbilical cord blood | Type 1 diabetes mellitus                                   | Phase II/III | NCT02138331     |
| MSC-EVs in dystrophic epidermolysis bullosa                               | Bone marrow (AGLE-102) | Dystrophic epidermolysis bullosa                           | Phase I     | NCT04173650     |
| Expanded access protocol on bone marrow MSCs derived extracellular vesicle infusion treatment for patients with COVID-19 associated ARDS | Bone marrow (ExoFlo®) | COVID-19 associated acute respiratory distress syndrome | Phase II    | NCT04657458 NCT04493242 |
| Clinical study of mesenchymal stem cell exosomes nebulizer for the treatment of ARDS | N/A             | COVID-19 associated acute respiratory distress syndrome   | Phase I/II   | NCT04602104     |
| Pilot clinical study on inhalation of MSC exosomes treating severe novel coronavirus pneumonia | Adipose tissue | COVID-19 pneumonia                                         | Phase I     | NCT04276987     |
| Effects of ASC secretome on human osteochondral explants                  | Adipose tissue  | Osteoarthritis and/or articular regeneration                | Observational | NCT04223622     |
| iExosomes in treating participants with metastatic pancreas cancer with KrasG12D mutation | N/A             | Metastatic pancreatic ductal adenocarcinoma                | Phase I     | NCT03608631     |
| Allogeneic MSC derived exosome in patients with acute ischemic stroke     | N/A             | Acute ischemic stroke                                       | Phase I/II   | NCT03384433     |

N/A, data not available. Fast track designation of commercial cell therapy products is also indicated.

In acute respiratory distress syndrome (ARDS) models, the administration of MSC-derived CD44+ EVs reduced the lung injury (Morrison et al., 2017). Remarkably, EV-mediated mitochondrial transfer induces a highly phagocytic and an anti-inflammatory macrophage phenotype (Morrison et al., 2017). In addition, MSC-derived exosomes remodel vascular network and diminish the hypoxia pulmonary hypertension in rodent models (Weiss et al., 2019). Systemically injected EVs have been shown to reduce both the collagen deposits and the inflammatory infiltrates in a murine model of silica-induced lung fibrosis (Choi M. et al., 2014).

The effects of MSC-derived EVs have been tested in other models of tissue fibrosis: treatment with EVs enriched in miRNA-let7c, a model of renal fibrosis, induced a downregulated expression of collagen IV, metalloproteinase-9, TGFβ1 and its receptor (Wang et al., 2016). Also, ECV enriched in miRNA-125b, that target Shh signaling activated in liver fibrosis, rescues liver progenitor cell expansion and stellate cell activation (Hyun et al., 2015). MSC-EVs containing miRNA22 improve cardiomyocyte survival in a murine model of myocardial ischemia-reperfusion (Arslan et al., 2013; Feng et al., 2014). Interestingly, CD69¬/¬ mice, which produce less exosomes, have shown significant reduced bone junctions. This problem can be recovered after injection of EVs isolated from MSC conditioned media, a process presumably mediated by RNAs (Furuta et al., 2016). EVs from embryonic MSCs promote cartilage regeneration in a rat osteochondral defect model by increasing both neof ormation of tissue and extracellular matrix components (Zhang et al., 2016), whereas exposure of MSC-derived EVs increases stem cell engraftment in irradiated bone marrow (Wen et al., 2016). Effects of MSC-derived EVs on the immune system reflect their origins and tend to show immunosuppressive properties. MSC-derived EVs containing miRNA inhibit macrophage activation by controlling NF-κB activation and induce changes in the profile of expression of several immune molecules, including IL-1β, COX-2, IL-10, TNF-α, MyD88, TLR-1, -4, -5, -7-9, IRAK1, and TRAF6 (Phinney et al., 2015). On the other hand, EVs from MSCs obtained from bone
discussed is shown in Figure 1. Firstly, we reported data on the phenotypical and functional characteristics of MSCs highlighting the difficulties to get specific markers that would allow to isolate enriched, homogeneous MSC subpopulations and to identify one or a few molecules masters for governing their properties.

MSC were used for the first time as cellular pharmaceutical agents in humans in 1995 (Lazarus et al., 1995). After several years utilizing MSCs as therapeutical agents, numerous questions on their behavior remain unsolved, including the heterogeneity of the MSC populations in the final product, the adequate conditions to activate in vivo their immunomodulatory capabilities, the consequences of the banking procedures, the best route for their delivery, the use of allogeneic vs. autologous cells, the problems to reach the target host tissues, their response to stressful conditions, specially hypoxia, or the real therapeutic relevance of products secreted by MSCs, such as the soluble fraction of their secretome or EVs.

Accordingly, we have summarized recent published results on these issues in an attempt to provide new approaches for a better clinical application of the named "MSCs-2.0." On the other hand, it is urgent a universal standardization of the protocols for manufacturing MSCs such as MSC culture and banking conditions, and also the route of cell delivery, the optimal dosage and the best way to use allogeneic vs. autologous MSCs. The available results on the effects of cryopreservation on MSC biology are contradictory and, although the use of allogeneic MSCs exhibit evident advantages in cell therapy, it is important to recognize their unquestionable immunogenicity, although immune responses elicited by allogeneic MSCs appear to be lower or less aggressive than autologous ones, presumably because a balance between immunogenicity and release of immunosuppressive factors is established in these circumstances.

Differences between MSC homing in preclinical models and humans must be conclusively clarified as well as the mechanisms governing the MSC homing into the target tissues by their relevance for a definitive establishment of the best route for MSC delivery, according to the disease to be treated. On the other hand, because MSC-mediated thromboembolism limits the MSC migration to the target tissues, this physiological condition, would be carefully evaluated before the systemic infusion of MSCs. Some simple, although transient, chemical manipulations of MSCs for improving their homing are highly promising but require technical optimization and a better knowledge on their consequences for the MSC biology. Also, usage of MSCs on scaffolds of diverse origin is complex and needs further research and improvement.

As indicated, to manipulate the whole factors known to affect MSC behavior is highly improbable since the therapeutic application of MSCs in a concrete disease requires the strengthening of the action of one or few discrete molecules. As summarized herein, genetic procedures have been attempted in the last years. However, this approach has the same problems than those reported in gene therapies applying other cell types. On the other hand, it is obvious that MSC engineering is a robust technology extensively tested in numerous experimental models but the translation of these results to the clinical practice need more time and research to be successful.

Apart from gene overexpression procedures, MSCs can be engineered changing the culture conditions by using 3D cultures or hypoxic conditions, or adhering distinct types of nanoparticles to the MSC membrane. Hypoxia has been frequently used as a preconditioning factor that favors MSC stemness and proliferation, and exhibit pro-angiogenic, anti-oxidant and anti-apoptotic effects.

EVs obtained from MSC secretome have provided in the last years numerous although frequently contradictory results but few effective clinical trials. Unfortunately, their heterogeneous condition, the lack of specific markers for establishing their true nature and, in general, the absence of information on the mechanisms controlling their effects, make difficult their therapeutic use, although increased numbers of clinical trials are being currently reported. It is therefore important to establish conclusively their real clinical value.

In summary, many of these research fields that try to improve MSC efficiency are ongoing with promising preclinical results, although the translation of their findings to the clinical practice seems to be yet remote.

**AUTHOR CONTRIBUTIONS**

DG-B, JS, MG-A, RY, RH-S, AC, MF-G, MH-R, ÓQ-B, JB, DG-O, JM, and AZ contributed to intellectual discussion of the findings. DG-B, JS, MG-A, RY, and AZ supervised the writing and drafting the manuscript. All the authors revised and approved the final version of the manuscript.

**FUNDING**

This study was supported by the Spanish Ministry of Science, Innovation and Universities (RTI2018-093938-B-I00), the Carlos III Health Institute through the Spanish Network of Cell Therapy (TerCel), RETICS subprogram of the I+D+i 2013–2016 Spanish National Plan, projects RD16/0011/0001, RD16/0011/0002, RD16/0011/0011, and RD16/0011/0013 (co-funded by European Regional Development Fund), and the Regional Government of Madrid (S2017/BMD-3692, Avancell-CM).
REFERENCES

Abdi, R., Moore, R., Sakai, S., Donnelly, C. B., Mounayar, M., and Sackstein, R. (2015). HCELL expression on murine MSC licenses pancreatectropism and confers durable reversal of autoimmune diabetes in NOD mice. Stem Cells 33, 1523–1531. doi: 10.1002/stem.1948

Ahlulwala, A., and Tarnawski, A. S. (2012). Critical role of hypoxia sensor–HIF-1alpha in VEGF gene activation. Implications for angiogenesis and tissue injury healing. Curr. Med. Chem. 19, 90–97. doi: 10.2174/092986712803413944

Alcayaya-Miganda, F., Cuenca, J., Martin, A., Conteras, L., Figueroa, F. E., and Khoury, M. (2015). Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis. Stem Cell Res. Ther. 6:199. doi: 10.1186/s13287-015-0192-0

Alfaro, D., Rodriguez-Sosa, M. A., and Zapata, A. G. (2020). Ephi/ephrin signaling and biology of mesenchymal stromal/stem cells. J. Clin. Med. 9:310. doi: 10.3390/jcm9020310

Amable, P. R., Teixeira, M. V., Carias, R. B., Granjeiro, J. M., and Borovec, R. (2014). Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly. Stem Cell Res. Ther. 5:53. doi: 10.1186/s13287-014-0042-8

Anderson, P., Souza-Moreira, L., Morell, M., Caro, M., O’Valle, F., Gonzalez-Rey, E., et al. (2013). Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis. Gut 62, 1131–1141. doi: 10.1136/gutjnl-2012-302152

Ankrum, J. A.,ong, J. F., and Karp, J. M. (2014). Mesenchymal stem cells: immune evasive, not immune privileged. Nat. Biotechnol. 32, 252–260. doi: 10.1038/nbt.2816

Arbab, A. S., Jordan, E. K., Wilson, L. B., Yocum, G. T., Lewis, B. K., and Frank, J. A. (2004). In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum. Gene Ther. 15, 351–360. doi: 10.1089/hum.2004.0432299506

Arslan, L., Fai, R. C., Smeets, M. B., Akeryod, L., Choo, A., Agour, E. N., et al. (2013). Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 10, 301–312. doi: 10.1016/j.scr.2013.01.002

Avivar-Valderas, A., Martin-Martin, C., Ramirez, C., Del Rio, B., Menta, R., Arslan, F., Lai, R. C., Smeets, M. B., Akeroyd, L., Choo, A., et al. (2013). Adipose-derived mesenchymal stromal cells induce macrophage polarization in ischemic kidney injury. Stem Cell Res. Ther. 4:244. doi: 10.1186/1479-5876-4-244

Bloor, A. J. C., Patel, A., Griffin, J. E., Gillette, M. H., Radia, R., Yeung, D. T., et al. (2020). Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat. Med. 26, 1720–1725. doi: 10.1038/s41591-020-1050-x

Braza, F., Diou, S., Forest, V., Sauzeau, V., Hassoun, D., Chesne, J., et al. (2016). Mesenchymal stem cells induce suppressive macrophages through phagocytosis in a mouse model of asthma. Stem Cells 34, 1836–1845. doi: 10.1002/stem.2344

Bister, N., Pistone, C., Huremagic, B., Jölkkonen, J., Giugno, R., and Malm, T. (2020). Hypoxia and extracellular vesicles: a review on methods, vesicular cargo and functions. J. Extracell. Vesicles 10, e12002. doi: 10.1002/jev2.12002

Chang, C. L., Leu, S., Sung, H. C., Zhen, Y. Y., Chen, C. L., and Chen, A., et al. (2012). Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in rat sepsis syndrome induced by cecal puncture and ligation. J. Transl. Med. 10:244. doi: 10.1186/1479-5876-10-244

Chang, S. C., Huang, H., Qu, Y. R., Chen, C. K., Mardini, S., et al. (2004). Cranial repair using BMP-2 gene engineered bone marrow stromal cells. J. Surg. Res. 119, 85–91. doi: 10.1016/j.jss.2003.08.003

Chang, S. C., Huang, H. L., Chen, C. K., Chung, H. Y., Lu, Y. L., et al. (2003). Ex vivo gene therapy in autologous bone marrow stromal stem cells for tissue-engineered maxillofacial bone regeneration. Gene Ther. 10, 2013–2019. doi: 10.1038/sj.gt.3302106

Chang, S. C., Chung, H. Y., Tai, C. L., Chen, P. K., Lin, T. M., and Jeng, L. B. (2010). Repair of large cranial defects by BMP-2 expressing bone marrow stromal cells: comparison between alginate and collagen type I systems. J. Biomed. Mater. Res. A 94, 433–441. doi: 10.1002/jbm.a.32685

Choi, M., Ban, T., and Rhim, T. (2014). Therapeutic use of stem cell transplantation for fistulas of crohn’s disease patients. Mol. Cells 33, 199–206. doi: 10.1002/1439-0319.molc.201404065

Choi, J. R., Pingguan-Murphy, B., Wan Abas, W. A., Noor Azmi, M. A., Omar, S. Z., Chua, K. H., et al. (2019). Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in rat sepsis syndrome induced by cecal puncture and ligation. J. Transl. Med. 10:244. doi: 10.1186/1479-5876-10-244

Caplan, A. I. (1991). Mesenchymal stem cells. J. Orthop. Res. 9, 641–650. doi: 10.1016/0742-8300(91)90050-4

Caplan, A. I., Olson, S. D., Kumar, A., Brachat, K. S., Wenzel, P., et al. (2019). Mesenchymal stem cell therapeutic delivery: translational challenges to clinical application. Front. Immunol. 10:1645. doi: 10.3389/fimmu.2019.01645

Carter, K., Lee, H. J., Na, K. S., Fernandes-Cunha, G. M., Blanco, I. J., Djallal, A., et al. (2019). Characterizing the impact of 2D and 3D culture conditions on the therapeutic effects of human mesenchymal stem cell secretome on corneal wound healing in vitro and ex vivo. Acta Biomater. 99, 247–257. doi: 10.1016/j.actbio.2019.09.022

Chen, L., Xu, Y., Zhao, J., Zhang, Z., Yang, R., Xie, J., et al. (2014). Conditioned medium from hypoxic bone marrow–derived mesenchymal stem cells enhances wound healing in mice. PLoS One 9:e96161. doi: 10.1371/journal.pone.0096161

Cheng, H., Byrksa-Bishop, M., Zhang, C. T., Kastrup, C. J., Huang, W. S., Tai, A. K., et al. (2012). Stem cell membrane engineering for cell rolling using peptide conjugation and tuning of cell–selectin interaction kinetics. Biomaterials 33, 5004–5012. doi: 10.1016/j.biomaterials.2012.03.065

Choi, J. R., Pingguan-Murphy, B., Wan Abas, W. A., Noor Azmi, M. A., Omar, S. Z., Chua, K. H., et al. (2019). Impact of low oxygen tension on stemness, proliferation and differentiation potential of human adipose-derived stem cells. Biochem. Biophys. Res. Commun. 448, 218–224. doi: 10.1016/j.bbrc.2014.04.096

Choi, M., Ban, T., and Rhim, T. (2014). Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of mesoviscelu released from mesenchymal stem cell. Mol. Cells 37, 133–139. doi: 10.14348/molcells.2014.3217

Chou, K. J., Lee, P. T., Chen, C. L., Hsu, C. Y., Huang, W. C., Huang, C. W., et al. (2012). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105, 2214–2219. doi: 10.1182/blood-2004-07-2921
set of biologically functional chemokine receptors. *Stem Cells* 24, 1030–1041. doi: 10.1634/stemcells.2005-0319

Huang, W., Zhang, D., Millard, R. W., Wang, T., Zhao, T., Fan, G. C., et al. (2010). Gene manipulated peritoneal cell patch repairs infarcted myocardium. *J. Mol. Cell. Cardiol.* 48, 702–712. doi: 10.1016/j.yjmcc.2009.10.032

Hynynen, J., Wang, S., Kim, J., Kim, G. J., and Jung, Y. (2015). MicroRNA125b-mediated Hedgehog signaling influences liver regeneration by choricnic plate-derived mesenchymal stem cells. *Sci. Rep.* 5:14135. doi: 10.1038/srep14135

Imtiyaz, H. Z., and Simon, M. C. (2010). Hypoxia-inducible factors as essential regulators of inflammation. *Curr. Top. Microbiol. Immunol.* 345, 105–120. doi: 10.1007/82_2010_74

Izadpanah, R., Kaushal, D., Kriedt, C., Tsien, F., Patel, B., Dufour, J., et al. (2008). Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. *Stem Cells* 28, 2229–2238. doi: 10.1002/stem.544

Kuci, Z., Konig, H., Kreyenberg, H., Bunos, M., Jauch, A., Janssen, J. W., et al. (2016). Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey. *Haematologica* 101, 985–994. doi: 10.3324/haematol.2015.140368

Kusuma, G. D., Cartwheel, J., Lim, J., and Frith, J. E. (2017). Effect of the microenvironment on mesenchymal stem cell paracrine signaling: opportunities to engineer the therapeutic effect. *Stem Cells Dev.* 26, 617–631. doi: 10.1089/scd.2016.0349

Langer, H. F., Sterllos, K., Steinghen, C., Frohlofer, A., Schonbenger, T., Kramer, B., et al. (2009). Platelet derived bFGF mediates vascular integrative mechanisms of mesenchymal stem cells in vitro. *J. Mol. Cell. Cardiol.* 47, 315–325. doi: 10.1016/j.yjmcc.2009.03.011

Langhans, S. A. (2018). Three-dimensional in vitro cell culture models in drug discovery and drug repositioning. *Front. Pharmacol.* 9. doi: 10.3389/fphar.2018.00006

Lazarus, H. M., Haynesworth, S. E., Gerson, S. L., Rosenthal, N. S., and Caplan, A. I. (1995). Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. *Bone Marrow Transplantation* 16, 557–564.

Le Blanc, K., Tammi, C., Rosendahl, K., Zetterberg, E., and Ringden, O. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. *Exp. Hematol* 31, 890–896. doi: 10.1016/s0301-472x(03)00110-3

Leclerc, M., Naserian, S., Pilon, C., Thiolat, A., Martin, G. H., Pouchy, C., et al. (2016). Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. *Blood* 128, 1651–1659. doi: 10.1182/blood-2016-02-708084

Levy, O., Zhao, W., Mortensen, I. J., Leblanc, S., Tsang, K., Fu, M., et al. (2013). mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation. *Blood* 122, e23–e32. doi: 10.1182/blood-2013-04-495119

Li, T., Yan, Y., Wang, B., Qian, H., Zhang, X., Shen, L., et al. (2013). Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. *Stem Cells Dev.* 22, 845–854. doi: 10.1089/scd.2012.0395

Li, W., Ma, N., Ong, L. L., Nesselmann, C., Klopsch, C., Ladirov, Y., et al. (2007). Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. *Stem Cells* 25, 2118–2127. doi: 10.1634/stemcells.2006-0771

Li, X. Y., Ding, J., Zheng, Z. H., Li, X. Y., Wu, Z. B., and Zhu, P. (2012). Long-term culture in vitro impairs the immunosuppressive activity of mesenchymal stem cells on T cells. *Mol. Med. Rep.* 6, 1183–1189. doi: 10.3892/mmr.2012.1039

Lian, J., Lv, S., Liu, C., Liu, Y., Wang, S., Guo, X., et al. (2016). Effects of serial passage on the characteristics and cardiac and neural differentiation of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells. *Stem Cells Int.* 2016, 1051924. doi: 10.1155/2016/1051924

Liao, W., Pham, V., Liu, L., Biazarfar, M., Pone, E. I., Zhang, S. X., et al. (2016). Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis. *Biometrics* 77, 87–97. doi: 10.1016/j.biomet.2015.11.005

Lin, C. Y., Chang, Y. H., Lin, K. J., Yen, T. C., Tai, C. L., Chen, C. Y., et al. (2010). The healing of critical-sized femoral segmental bone defects in rabbits using hybrid baculovirus-engineered mesenchymal stem cells. *Biomaterials* 31, 3222–3230. doi: 10.1016/j.biomaterials.2010.01.030

Lin, C. Y., Lin, K. J., Kao, C. Y., Chen, M. C., Lo, W. H., Yen, T. C., et al. (2011). The role of adipose-derived stem cells engineered with the persistently expressing hybrid baculovirus in the healing of massive bone defects. *Biomaterials* 32, 6505–6514. doi: 10.1016/j.biomaterials.2011.05.059
Lin, C. Y., Lin, K. J., Li, K. C., Sung, L. Y., Hsu, S., Lu, C. H., et al. (2012). Immune responses during healing of massive segmental femoral bone defects mediated by hybrid baculovirus-engineered ASCs. *Biomaterials* 33, 7422–7434. doi: 10.1016/j.biomaterials.2012.06.083

Lin, C. Y., Wang, Y. H., Li, K. C., Sung, L. Y., Yeh, C. L., Lin, K. J., et al. (2015). Healing of massive segmental femoral bone defects in minipigs by allogenic ASCs engineered with FLPo/Frt-based baculovirus vectors. *Biomaterials* 50, 98–106. doi: 10.1016/j.biomaterials.2015.01.052

Liu, C., Fan, Y., Zhou, L., Zhu, H. Y., Song, Y. C., Hu, L., et al. (2015). Pretreatment of mesenchymal stem cells with angiotensin II enhances paracrine effects, angiogenesis, gap junction formation and therapeutic efficacy for myocardial infarction. *Int. J. Cardiol.* 188, 22–32. doi: 10.1016/j.ijcard.2015.03.045

Liu, D. D., Ullah, M., Concepcion, W., Dahl, J. J., and Thakor, A. S. (2020). The role of ultrasound in enhancing mesenchymal stem cell-based therapies. *Stem Cells Transl. Med.* 9, 850–866. doi: 10.1002/stcm.19-0391

Liu, Y., Xu, M., Martin-Rendon, E., Watt, S., and Cui, Z. (2010). Cryopreservation of human bone marrow-derived mesenchymal stem cells with reduced dimethylsulfoxide and well-defined freezing solutions. *Biotechnol. Prog.* 26, 1653–1663. doi: 10.1002/bptp.644

Lo, C. Y., Antonopoulos, A., Dell, A., Haslam, S. M., Lee, T., and Neelamegham, S. (2013). The use of surface immobilization of P-selectin glycoprotein ligand-1 on mesenchymal stem cells to facilitate selectin mediated cell tethering and rolling. *Biomaterials* 34, 8213–8222. doi: 10.1016/j.biomaterials.2013.07.033

Lu, W., Fu, C., Song, L., Yao, Y., Zhang, X., Chen, Z., et al. (2013). Exposure to supernatants of macrophages that phagocytosed dead mesenchymal stem cells improves hypoxic cardiomyocytes survival. *Int. J. Cardiol.* 165, 333–340. doi: 10.1016/j.ijcard.2012.03.088

Luetzkendorf, J., Mueller, L. P., Mueller, T., Caysa, H., Nerger, K., and Schnoll, H. J. (2010). Growth inhibition of colorectal cancer by lentiviral TRAIL–transgenic human mesenchymal stem cells require their substantial intratumoral presence. *J. Cell. Mol. Med.* 14, 2292–2304. doi: 10.1111/j.1582-4934.2009.00794.x

Luetzkendorf, J., Nerger, K., Hering, J., Moegel, K., Hoffmann, K., Hoefers, C., Moll, G., Ignatowicz, L., Catar, R., Luecht, C., Sadeghi, B., Hamad, O., et al. (2015). Different procoagulant activity of therapeutic mesenchymal stem cells derived from bone marrow and Placental Decidua. *Stem Cells Dev.* 24, 2269–2279. doi: 10.1089/scd.2014.0120

Luetzkendorf, J., Moll, G., Moll, G., Jitschin, R., von Bahr, L., Rasmusson-Duprez, I., Sundberg, B., Lonnis, L., et al. (2011). Mesenchymal stromal cells engage complement and complement receptor bearing innate effector cells to modulate immune responses. *PLoS One* 6, e21703. doi: 10.1371/journal.pone.0021703

Moll, G., Rasmusson-Duprez, I., von Bahr, L., Connolly-Andersen, A. M., Elgue, G., Funke, L., et al. (2012). Are therapeutic human mesenchymal stem cells compatible with human blood? *Stem Cells* 30, 1565–1574. doi: 10.1002/stem.1111

Morrison, T. J., Jackson, M. V., Cunningham, E. K., Kissen-Penning, A., McAuley, D. F., O’Kane, C. M., et al. (2017). Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. *Am. J. Respir. Crit. Care Med.* 196, 1275–1286. doi: 10.1164/rccm.201701-0170OC

Mosser, D. M., and Zhang, X. (2008). Interleukin-10: new perspectives on an old cytokine. *Immunol. Rev.* 226, 205–218. doi: 10.1111/j.1600-065X.2007.00706.x

Mukherjee, S., Agrawal, M., Bakshi, A., Sawant, S., Thomas, L., Fujii, N., et al. (2020). Chemokine SDF1 mediated bone regeneration using biodegradable (P,D)-lactide-co-glycolide) 3D scaffolds and bone marrow-derived mesenchymal stem cells: implication for the development of an “Off-the-Shelf” pharmacologically active construct. *Biomacromolecules* 21, 4888–4903. doi: 10.1021/acs.biomac.0c01134

Nakajima, M., Nito, C., Sowa, K., Suda, S., Nishiyama, Y., Nakamura-Takahashi, A., et al. (2017). Mesenchymal stem cells overexpressing interleukin-10 promote neuroprotection in experimental acute ischemic stroke. *Mol. Ther. Methods Clin. Dev.* 6, 102–111. doi: 10.1016/j.omtm.2017.06.005

Nakamura, Y., Ishikawa, H., Kawai, K., Tabata, Y., and Suzuki, S. (2013). Enhanced wound healing by topical administration of mesenchymal stem cells transplanted with stromal cell-derived factor-1. *Biomaterials* 34, 9393–9400. doi: 10.1016/j.biomaterials.2013.08.053

Narain, A., Asawa, S., Chhabria, V., and Patil-Sen, Y. (2017). Cell membrane coated nanoparticles: next-generation therapeutics. *Nanomedicine (Lond.)* 12, 2677–2692. doi: 10.2217/nmm-2017-0225

Naserian, S., Abdelgawad, M. E., Afshar Bakhshlo, M., Ha, G., Arouche, N., Cohen, J. L., et al. (2020). The TNF/TNF-F2 signaling pathway is a key regulatory factor in endothelial progenitor cell immunosuppressive effect. *Cell Commun. Signal.* 18, 94. doi: 10.1186/s12964-020-00564-3

Nitzschke, F., Muller, C., Lukomska, B., Jolkonen, J., Deten, A., and Bolze, J. (2017). Concise review: MSC adhesion cascade-insights into homing and transendothelial migration. *Stem Cells* 35, 1446–1460. doi: 10.1002/stem.2614

Noone, C., Kilm, A., English, K., O’Bea, S., and Mahon, B. P. (2013). IFN-gamma stimulated human umbilical-tissue-derived cells potently suppress NK activation and resist NK-mediated cytotoxicity in vitro. *Stem Cells Dev.* 22, 3003–3014. doi: 10.1089/scd.2013.0028
Phinney, D. G., Baddoo, M., Dutreil, M., Gaupp, D., Lai, W. T., and Isakova, I. A. (2006). Murine mesenchymal stem cells transplanted to the central nervous system of neonatal versus adult mice exhibit distinct engraftment kinetics and express receptors that guide neuronal cell migration. Stem Cells Dev. 15, 437–447. doi: 10.1089/scd.2006.15.437

Phinney, D. G., Di Giuseppe, M., Njah, J. K., Douglas, R., Mosca, J. D., and Santoro, N. V. (2015). Enhancement of the therapeutic capacity of mesenchymal stem cells by genetic modification: a systematic review. Front. Cell Dev. Biol. 11:274. doi: 10.3389/fcell.2015.00274

Qi, H., Chen, G., Huang, Y., Si, Z., and Li, J. (2015). Foxp3-modified bone marrow mesenchymal stem cells promotes liver allograft tolerance through the generation of regulatory T cells in rats. J. Transl. Med. 13:274. doi: 10.1186/s12967-015-0638-2

Roemeling-van Rhijn, M., Korevaar, S. S., Leijs, M. J., van Osch, G. J., Svirshchevskaya, E. V., et al. (2018). Lipocalin 2 enhances mesenchymal stem cell-trafficking to bone. Biomaterials 175, 37–48. doi: 10.1016/j.biomaterials.2018.02.030

Shoda, H., Nagafuchi, Y., Tsuchida, Y., Sakurai, K., Sumitomo, S., Fujio, K., et al. (2007). Regulation of mitochondrial turnover and mitophagy and shuttle microRNAs. J. Cell Sci. 120, 1049–1055. doi: 10.1242/jcs.035084

Shi, M., Li, J., Liao, L., Chen, B., Li, B., Chen, L., et al. (2007). Regulation of immune responses by mesenchymal stem cell-derived exosomes improves the microenvironment of infarcted myocardium. Stem Cells 25, 1518–1527. doi: 10.1634/stemcells.2006-0577

Sarkar, D., Vemula, P. K., Teo, G. S., Spelke, D., Kernik, R., Wee le, Y., et al. (2008). Chemical engineering of mesenchymal stem cells to induce a cell rolling response. Bioconjug. Chem. 19, 2105–2109. doi: 10.1021/bc800354q

Sarafis, L., Taylor, A., Starkey, J., Harwood, R., Barrow, M., Comenge, J., et al. (2018). Non-invasive imaging reveals conditions that impact distribution and persistence of cells after in vivo administration. Stem Cell Res. Ther. 9:332. doi: 10.1186/s13287-018-1076-x

Schanz, J. T., Chim, H., and Whittem, M. (2007). Cell guidance in tissue engineering: SDF-1 mediates site-directed homing of mesenchymal stem cells within three-dimensional polycaprolactone scaffolds. Tissue Eng. 13, 2615–2624. doi: 10.1089/tmte.2006.0438

Schive, S. W., Mirlashari, M. R., Hasvold, G., Wang, M., Jøsensen, D., Gullestad, H. P., et al. (2017). Human adipose-derivated mesenchymal stem cells respond to short-term hypoxia by secreting factors beneficial for human islets in vivo and potentiate antidipabetic effect in vivo. Cell Med. 9, 103–116. doi: 10.3727/215517917X793401

Schräfstatter, I. U., Discipio, R. G., Zhao, M., and Khalil, O. M. (2017). Ca4 and Ca5 are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation. J. Immunol. 190, 3827–3836. doi: 10.4049/jimmunol.1800355

Seo, K. W., Lee, H. W., Oh, Y. I., Ahn, J. O., Koh, Y. R., Oh, S. H., et al. (2011). Anti-tumor effects of canine adipose tissue-derived mesenchymal stem cell-based interferon-beta gene therapy and cisplatin in a mouse melanoma model. Cytoterapy 13, 944–955. doi: 10.1007/s10561-011-9486-4

Shammar, R., El-Kadiry, A. E., Abuabara, J., and Rafai, M. (2020). Mesenchymal stem cells beyond regenerative medicine. Front. Cell Dev. Biol. 8:587776. doi: 10.3389/fcell.2020.00072

Shen, W., Chen, X., Chen, J., Yin, Z., Heng, B. C., Chen, W., et al. (2010). The effect of incorporation of exogenous stem-cell-derived factor-1 alpha within a knitted silk-collagen sponge scaffold on tendon regeneration. Biomaterials 31, 7239–7249. doi: 10.1016/j.biomaterials.2010.05.040

Shi, M., Li, J., Liao, L., Chen, B., Li, B., Chen, L., et al. (2007). Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica 92, 897–904. doi: 10.3724/haematol.10669

Shoda, H., Nagafuchi, Y., Tsuchida, Y., Sakurai, K., Sumitomo, S., Fujio, K., et al. (2017). Increased serum concentrations of IL-1 beta, IL-21 and Th17 cells in overweight patients with rheumatoid arthritis. Arthritis Res. Ther. 19:111. doi: 10.1186/s13075-013-1298-2

Siod, M., Mobergliën, A., Boudabous, A., and Flosand, Y. (2010). Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation. Scand. J. Immunol. 71, 267–274. doi: 10.1111/j.1365-3083.2010.02378.x

Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C., and Moretta, L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107, 1484–1490. doi: 10.1182/blood-2005-07-2775

Sun, Y., Wang, Y., Zhou, L., Zou, Y., Huang, G., Gao, G., et al. (2018). Spheroid-cultured human umbilical cord-derived mesenchymal stem cells attenuate hepatic ischemia-reperfusion injury in rats. Sci. Rep. 8:2518. doi: 10.1038/s41598-018-20975-0

Sung, D. K., Chang, Y. S., Sung, S. I., Yoo, H. S., Ahn, S. Y., and Park, W. S. (2016). Anti-bacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta- defensin- 2 via toll-like receptor 4 signalling. Cell. Microbiol. 18, 424–436. doi: 10.1111/cmi.12522

Sung, P. H., Chang, C. L., Tsi, T. H., Chang, L. T., Leu, S., Chen, Y. L., et al. (2013). Apoptotic adipose-derived mesenchymal stem cell therapy protects against lung and kidney injury in sepsis syndrome caused by cecal ligation puncture in rats. Stem Cell Res. Ther. 4:155. doi: 10.1186/scrt385

Teixeira, F. G., Carvalho, M. M., Neves-Carvalho, A., Panchalingam, K. M., Behie, L. A., Pinto, L., et al. (2015). Secretome of mesenchymal progenitors of human mesenchymal stem cells is mediated by secretion of beta- defensin-2 via toll-like receptor 4 signalling. Cell. Microbiol. 18, 424–436. doi: 10.1111/cmi.12522

Teng, X., Chen, L., Chen, W., Yang, J., Yang, Z., and Shen, Z. (2015). Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted...
Thevenot, P. T., Nair, A. M., Shen, J., Lotfi, P., Ko, C. Y., and Tang, L. (2010). The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials 31, 3997–4008. doi: 10.1016/j.biomaterials.2010.01.144

Thum, T., Bauersachs, J., Poole-Wilson, P. A., Volk, H. D., and Anker, S. D. (2005). The lung microvasculature: a novel route for drug delivery to the lung. J. Heart Lung Transplant. 24, 1022–1030. doi: 10.1016/j.healun.2004.11.027

van Bahr, L., Batsis, I., Moll, G., Hagg, M., Szakos, A., Sundberg, B., et al. (2012). Mesenchymal stromal cell homing: barriers and functions of intercellular mitochondrial transfer. Front. Cell Dev. Biol. 4:107. doi: 10.3389/fcell.2016.00107

Zhang, D., Huang, W., Dai, B., Zhao, T., Ashraf, A., Millard, R. W., et al. (2015). Engineered mesenchymal stromal stem cells differentiate into insulin-producing beta cells. J. Transl. Med. 13:138–151. doi: 10.1186/s12958-015-0074-9

Zhang, S., Zhu, L., Luo, K., Mu, R., Chen, F., Wei, X., et al. (2017). Mesenchymal stromal cells deliver exogenous miR-150-5p via exosomes to augment renal fibrosis. Mol. Ther. 25, 2923–2934. doi: 10.1016/j.ymthe.2016.9.012

Zhang, D., Huang, W., Dai, B., Zhao, T., Ashraf, A., Millard, R. W., et al. (2015). Engineered mesenchymal stromal stem cells differentiate into insulin-producing beta cells. J. Transl. Med. 13:138–151. doi: 10.1186/s12958-015-0074-9

Zhang, S., Zhu, L., Luo, K., Mu, R., Chen, F., Wei, X., et al. (2017). Mesenchymal stromal cells deliver exogenous miR-150-5p via exosomes to augment renal fibrosis. Mol. Ther. 25, 2923–2934. doi: 10.1016/j.ymthe.2016.9.012

Zhang, S., Zhu, L., Luo, K., Mu, R., Chen, F., Wei, X., et al. (2017). Chitosan composite scaffold combined with bone marrow-derived mesenchymal stem cells for bone regeneration: in vitro and in vivo evaluation. Oncotarget 8, 110890–110903. doi: 10.18632/oncotarget.22917

Zhang, A., Wang, Y., Ye, Z., Xie, H., Zhou, L., and Zheng, S. (2010). Mechanism of TNF-alpha-induced migration and hepatocyte growth factor production in human mesenchymal stem cells. J. Cell. Biochem. 111, 469–475. doi: 10.1002/jcb.22729

Zhang, D., Huang, W., Dai, B., Zhao, T., Ashraf, A., Millard, R. W., et al. (2010). Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts. Am. J. Physiol. Heart Circ. Physiol. 299, H1339–H1347. doi: 10.1152/ajpheart.00102.2010

Zhang, S., Zhu, L., Luo, K., Mu, R., Chen, F., Wei, X., et al. (2017). Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts. Am. J. Physiol. Heart Circ. Physiol. 299, H1339–H1347. doi: 10.1152/ajpheart.00102.2010

Zhang, J., Huang, X., Wang, H., Liu, X., Zhang, T., Wang, Y., et al. (2015). The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res. Ther. 6:234. doi: 10.1186/s13287-015-0240-9

Zhang, J., Zhou, S., Zhou, Y., Feng, F., Wang, Q., Zhu, X., et al. (2014). Hepatocyte growth factor gene-modified adipose-derived mesenchymal stem cells ameliorate radiation induced liver damage in a rat model. PLoS One 9:e114670. doi: 10.1371/journal.pone.0114670

Zhang, S., Chu, C. W., Lai, R. C., Lim, S. K., Hui, J. H., and Toh, W. S. (2016). Mesenchymal stem cells ameliorate acute kidney injury through enhanced angiogenic and antioxidative capacities. Biomed. Res. Int. 2014:462472. doi: 10.1155/2014/462472

Zhao, C., Pu, Y., Zhang, H., Hu, X., Zhang, R. He, S., et al. (2020). IL-10 modified human mesenchymal stem cells inhibit pancreatic cancer growth through angiogenesis inhibition. J. Cancer 11, 5345–5352. doi: 10.7150/jca.38062

Zhao, C., Pu, Y., Zhang, H., Hu, X., Zhang, R. He, S., et al. (2020). IL-10 modified human mesenchymal stem cells inhibit pancreatic cancer growth through angiogenesis inhibition. J. Cancer 11, 5345–5352. doi: 10.7150/jca.38062

Zheng, L., Zhang, D., Chen, X., Yang, L., Wei, Y., and Zhao, X. (2012). Antitumor activities of human placenta-derived mesenchymal stem cells expressing mulcythymus contributing to angiogenesis and anti-inflammation. Cell. Physiol. Biochem. 37, 2415–2424. doi: 10.1159/0003438594

Thum, T., Bauersachs, J., Poole-Wilson, P. A., Volk, H. D., and Anker, S. D. (2005). The lung microvasculature: a novel route for drug delivery to the lung. J. Heart Lung Transplant. 24, 1022–1030. doi: 10.1016/j.healun.2004.11.027

Watanabe, Y., Tsuchiya, A., and Terai, S. (2021). Review: the development of mesenchymal stem cell therapy to treat liver diseases. J. Orthop. Res. 21, 1137–1148. doi: 10.1002/jort.2017.06.0073

Zhang, D., Huang, W., Dai, B., Zhao, T., Ashraf, A., Millard, R. W., et al. (2010). Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts. Am. J. Physiol. Heart Circ. Physiol. 299, H1339–H1347. doi: 10.1152/ajpheart.00102.2010

Zhang, J., Huang, X., Wang, H., Liu, X., Zhang, T., Wang, Y., et al. (2015). The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy. Stem Cell Res. Ther. 6:234. doi: 10.1186/s13287-015-0240-9

Zhang, J., Zhou, S., Zhou, Y., Feng, F., Wang, Q., Zhu, X., et al. (2014). Hepatocyte growth factor gene-modified adipose-derived mesenchymal stem cells ameliorate radiation induced liver damage in a rat model. PLoS One 9:e114670. doi: 10.1371/journal.pone.0114670

Zhang, S., Chu, C. W., Lai, R. C., Lim, S. K., Hui, J. H., and Toh, W. S. (2016). Mesenchymal stem cells ameliorate acute kidney injury through enhanced angiogenic and antioxidative capacities. Biomed. Res. Int. 2014:462472. doi: 10.1155/2014/462472

Zhao, C., Pu, Y., Zhang, H., Hu, X., Zhang, R. He, S., et al. (2020). IL-10 modified human mesenchymal stem cells inhibit pancreatic cancer growth through angiogenesis inhibition. J. Cancer 11, 5345–5352. doi: 10.7150/jca.38062

Zhao, C., Pu, Y., Zhang, H., Hu, X., Zhang, R. He, S., et al. (2020). IL-10 modified human mesenchymal stem cells inhibit pancreatic cancer growth through angiogenesis inhibition. J. Cancer 11, 5345–5352. doi: 10.7150/jca.38062

Zheng, L., Zhang, D., Chen, X., Yang, L., Wei, Y., and Zhao, X. (2012). Antitumor activities of human placenta-derived mesenchymal stem cells expressing
endostatin on ovarian cancer. *PLoS One* 7:e39119. doi: 10.1371/journal.pone.0039119

Zheng, X. B., He, X. W., Zhang, L. J., Qin, H. B., Lin, X. T., Liu, X. H., et al. (2019). Bone marrow-derived CXCR4-overexpressing MSCs display increased homing to intestine and ameliorate colitis-associated tumorigenesis in mice. *Gastroenterol. Rep. (Oxf.)* 7, 127–138. doi: 10.1093/gastro/goy017

Zhou, Z., Peng, X., Insolera, R., Fink, D. J., and Mata, M. (2009). Interleukin-10 provides direct trophic support to neurons. *J. Neurochem.* 110, 1617–1627. doi: 10.1111/j.1471-4159.2009.06263.x

Zhu, K., Lai, H., Guo, C., Xu, D., and Wang, C. (2012). Novel vascular endothelial growth factor gene delivery system-manipulated mesenchymal stem cells repair infarcted myocardium. *Exp. Biol. Med. (Maywood)* 237, 678–687. doi: 10.1258/ebm.2012.011430

Ziadloo, A., Burks, S. R., Gold, E. M., Lewis, B. K., Chaudhry, A., Merino, M. J., et al. (2012). Enhanced homing permeability and retention of bone marrow stromal cells by noninvasive pulsed focused ultrasound. *Stem Cells* 30, 1216–1227. doi: 10.1002/stem.1099

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 García-Bernal, García-Arranz, Yáñez, Hervás-Salcedo, Cortés, Fernández-García, Hernando-Rodríguez, Quintana-Bustamante, Bueren, García-Olmo, Moraleda, Segovia and Zapata. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.